<DOC>
	<DOCNO>NCT00480246</DOCNO>
	<brief_summary>This single dose , open-label , 2-panel ( Parts A B ) PET study investigate degree occupancy dopamine 2 receptor ( D2_RO ) human brain single oral dos BL-1020 Perphenazine ( Trilafon® , hereafter call Perphenazine ) healthy male subject . In Part A D2_RO investigate study compound BL-1020 Part B D2_RO BL-1020 compare D2_RO Perphenazine , reference compound .</brief_summary>
	<brief_title>A Positron Emission Tomography ( PET ) Study Assess Degree Dopamine-2 ( D2 ) Receptor Occupancy Human Brain After Single Doses BL-1020 Perphenazine Healthy Male Subjects Using 11CRaclopride PET Tracer</brief_title>
	<detailed_description />
	<mesh_term>Perphenazine</mesh_term>
	<criteria>1 . Voluntarily sign write informed consent agreement approve Independent Ethics Committee ( IEC ) explanation nature objective study prior study specific procedure . 2 . Healthy male subject age 21 35 ( inclusive ) . 3 . Body Mass Index ( BMI ) ( weight [ kg ] / ( height [ ] x height [ ] ) ) ≥ 18 &lt; 29 kg/m2 . 4 . Nonsmokers refrain smoke nicotine containing product last 1 month dose administration . 5 . Good health , base upon result medical history , physical examination , ECG ( without clinically significant abnormality ) laboratory profile blood urine , include creatinine clearance , calculate use CockcroftGault formula ( upper limit eligibility 1.5 time upper normal limit ) . 6 . Normal blood pressure ( systolic blood pressure ≥ 95 ≤ 149 mmHg ; diastolic blood pressure ≥ 55 ≤ 89 mmHg ) measure 5 minute rest supine position . 7 . Pulse rate ≥ 45 ≤ 95 beats/min measure 5 minute rest supine position . 8 . Able communicate well investigator able comply requirement entire study . 1 . Intake prescribed medication Over Counter ( OTC ) medication , include herbal remedy , mineral vitamin preparation , within 14 day prior dose schedule receive study . Paracetamol allow , except within 24 hour PET scan . 2 . Demonstration active physical disease , acute chronic . 3 . Any gastrointestinal complaint within 7 day prior dose day . 4 . Any condition might interfere absorption investigational product , e.g . cholecystectomy ( gall bladder removal , cholecystolithiasis ) . 5 . Any relevant history chronic recurrent metabolic ( e.g. , diabetes ) , renal , hepatic , pulmonary , gastrointestinal ( e.g. , gastrointestinal disease , chronic gastritis peptic ulcer ) , neurological ( especially history seizure disorder ) , endocrinological , immunological , psychiatric cardiovascular disease , myopathy bleed tendency . 6 . Positive test result hepatitis B surface antigen ( HBsAg ) , antiHepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) . 7 . CYP2D6 genotype poor metabolizer . 8 . Relevant drug hypersensitivity , asthma , urticaria severe allergic diathesis well ongoing hay fever . 9 . Febrile infectious illness within 7 day prior dose day . 10 . Participation investigational drug study within 3 month prior dose day . 11 . Donation blood within 3 month prior dose day . 12 . History alcoholism moderate alcohol consumption ( &gt; 3 unit ethanol regularly per day &gt; 21 unit regularly per week ) . 13 . Consumption alcohol within 48 hour prior dose administration and/or positive alcohol breath test . 14 . History drug addiction positive drug urine screen amphetamine , benzodiazepine , cannabis , cocaine , methadone opiate . 15 . Consumption 5 cup coffee equivalent per day . 16 . Consumption xanthinecontaining food beverage , grapefruit juice within 48 hour prior dose administration . 17 . Previous participation PET investigation . 18 . Occupational exposure significant ionizing radiation . 19 . Having undergone clinical procedure involve significant exposure radiation ( exception e.g . dental X ray common Xrays chest extremity ) , judge investigator . 20 . Suffers claustrophobia . 21 . Unsuitability reason opinion investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>receptor oocupancy</keyword>
</DOC>